

(19) World Intellectual Property
Organization
International Bureau



528,802
23 MAR 2005



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026330 A1

- (51) International Patent Classification⁷: **A61K 38/17**
- (21) International Application Number:
PCT/BE2003/000158
- (22) International Filing Date:
23 September 2003 (23.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0222014.3 23 September 2002 (23.09.2002) GB
- (71) Applicants (for all designated States except US): **K.U. LEUVEN RESEARCH AND DEVELOPMENT** [BE/BE]; Groot Begijnhof 58-59, B-3000 Leuven (BE). **AARHUS UNIVERSITET** [DK/DK]; Nordre Ringgade 1, DK-8000 Aarhus C (DK). **AARHUS UNIVERSITY HOSPITAL** [DK/DK]; Aarhus Amt, Lyseng Allé 1, DK-8270 Højbjerg (DK).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **VAN DER BERGHE, Greta** [BE/BE]; Rue de Beaumont 77, B-1390 Grez-Doiceau (BE). **THIEL, Steffen** [DK/DK]; Nordtoftevej 11, DK-8240 Risskov (DK). **KRARUP HANSEN, Troels** [DK/DK]; Bygvangen 20, DK-8200 Aarhus N (DK).
- (74) Common Representative: **K.U. LEUVEN RESEARCH AND DEVELOPMENT**; Dr. Ivo Roelants- IPR Officer, Groot Begijnhof 58-59, B-3000 Leuven (BE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
— of inventorship (Rule 4.17(iv)) for US only
- Published:**
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS AND PREPARATIONS FOR CURING CRITICALLY ILL PATIENTS

(57) Abstract: The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further involves the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

WO 2004/026330 A1

METHODS AND PREPARATIONS FOR CURING CRITICALLY ILL PATIENTS

5 Technical Field

The present invention pertains to the use of a blood mannan-binding lectin (MBL) regulator for the manufacture of a life saving drug to treat or cure a critically ill patient. It further claims the use of measurements of MBL to predict mortality in critically ill ICU patients. One further aspect of present invention is to the use of monomers and oligomers of MBL in prophylactic and/or curative treatment of patients admitted to intensive care units (ICUs).

15 Background of the Invention

Mortality among patients with prolonged critical illness exceeds 20 percent, with most deaths being attributable to sepsis and multiple-organ failure (Van den Berghe G et al., N Engl J Med 2001;345(19):1359-67; Takala J, et al. N Engl J Med 1999;341(11):785-92). Each year, these conditions affect more than 500 000 patients in the United States alone (Wheeler AP et al. N.Engl.J.Med. 1999;340(3):207-14). An increased susceptibility to severe infections during critical illness, as well as adverse effects of an excessive systemic inflammatory response on organ function may be operative.

25 The average serum concentration of MBL in the adult population is between 1000-2000 ng/ml with very large variations (Turner MW and Hamvas RM. Rev. Immunogenet. 2000;2(3):305-22). The between-subjects differences in serum concentrations are primarily caused by genetic factors. Point mutations within exon 1 as well as in the promoter region of the MBL gene occur with high incidence. As a consequence, approximately one third of the population have MBL concentrations below 500 ng/ml, and more than 10% have concentrations below 50 ng/ml (Steffensen R, et al. J.Immunol.Methods 2000;241(1-2):33-42). Normally, within-subject variations of

MBL levels are very small (Hansen TK, et al. J.Clin.Endocrinol.Metab 2001;86(11):5383-8), but serum concentrations increase during acute phase responses (Thiel S, et al. Clin.Exp.Immunol. 1992;90(1):31-5) and can be specifically induced by growth hormone (GH) administration (Hansen TK, et al. J. Clin. Endocrinol.Metab 2001;86(11):5383-8). Deficiency of MBL is associated with an increased incidence of infections (Super M, et al. Lancet 1989;2(8674):1236-9; Koch A, et al. JAMA 2001;285(10):1316-21; Summerfield JA, et al. BMJ 1997;314(7089):1229-32; Garred P, et al Lancet 1995;346(8980):941-3), but due to the redundancy of the immune system the increased risk may only be apparent if other coexisting immunological abnormalities are present. In line with this, it was recently reported that low levels of MBL in patients receiving cancer chemotherapy are associated with an increased frequency of febrile neutropenic episodes and severe infections (Neth O, Hann I, et al. Lancet 2001;358(9282):614-8.; Peterslund NA, et al. Lancet 2001;358(9282):637-8). The impact of MBL concentrations on the course of disease in otherwise immunocompetent critically ill patients has not been studied yet and is an object present invention.

By present study was investigated how MBL affects outcome in critically ill patients. In all patients, irrespective of the treatment, the MBL concentrations increased significantly with the time of intensive care ($P < 0.0001$), a rise that was independent of the baseline MBL concentration, but attributable to the survivors. By present invention it was demonstrated that low MBL levels were at negative outcome in critically ill patients. MBL concentrations at baseline were almost three times higher in survivors than in non-survivors ($p = 0.04$).

This invention demonstrates that restoring MBL levels in critically ill patients to normal levels, preferable to a level above 250 $\mu\text{g/l}$ serum, more preferably to a level above 500 $\mu\text{g/l}$ serum, more preferably to a level above 1000 ng/ml and most preferably between 1000 ng/ml and 2000 ng/ml can be used to improve outcome such as the survival of critically ill patients in the intensive care unit (ICU). However, after this invention, it will be clear for the man skilled in the art that also active MBL derivatives or compounds of the group of biologically active substances, which stimu-

late hepatocytes to synthesise and/or release of MBL and consequently increase the level of circulating MBL can be used to obtain the same outcome.

The MBL is obtainable from various sources.

5 Mannan-binding lectin was first isolated from human serum in 1983 (Kawasaki N. et al, J. Biochem (Tokyo), 1983, 94, 937-947) by affinity chromatography on mannan-Sepharose (mannan coupled to a Sepharose matrix) in the presence of Ca-ions. Elution of MBL from the affinity column was performed by means of EDTA. Improved methods of mannose binding protein purification have been described in Ezewko-
10 witz Raymond US 5270199; S.M. Tan et al Biochemical journal Vol. 319 , no 2, 15 October 1996, pages 329- 332; R. Koppel et al. Journal of chromatography B.: Bio-medical Applications., vol. 662, no 2, 1994 pages 191-196.; D.C. Kilpatrick Transfusion Medicine, vol. 7 , no. 4, 1997 pages 289-294 and WO 99/64453 Laursen Inga. MBL can be isolated by passage down a mannose-Sepharose column as described
15 by Wild et al., Biochem. J., 210: 167-174 1983 or Drickamer et al., J. of Bio. Chemistry, 261: 6878-6887 1986. MBL can be produced in engineered cells. Recombinant MBL has been produced by mammalian cell culture (Ezekowitz, U.S. Pat. No. 5,270,1999) such as in myeloma cells, Chinese hamster ovary (CHO) cells, human hepatocytes, and human embryonic kidney (HEK) cells (Vorup-Jensen, T et al. Int-
20 Immunopharmacol. 2001 Apr; 1(4): 677-87) or by expression of MBL in methylo-trophic yeast strains as for instance described in US6337193.

Clinical grade MBL has been obtained and shown to be safe upon infusion. It has for instance already been demonstrated in patients with long disease that pooled human
25 donor plasma derived MBL can safely be administered to patients (Garred,-Peter; et al. Pediatr-Pulmonol. 2002 Mar; 33(3): 201-7). Moreover, present invention demonstrated for the first time an efficient MBL therapy for critically ill patients in the ICU, which were not previously been immunocompromised (e.g. not immunosuppressed after organ transplantation or by disease).

30

Furthermore it will be clear for the man skilled in the art that compounds of the group of biologically active substances which stimulate hepatocytes to synthesise

and or release MBL and consequently increase the level of circulating MBL can be used to in a prophylactic or therapeutic treatment to improve outcome and survivability of critically ill patients in the ICU. Such compound with an activity of promoting the secretion of MBL were already well disclosed before the moment of this invention such as growth hormone (Hansen, T-Ket al. J-Clin-Endocrinol-Metab. 2001 Nov; 86(11): 5383-8).

The general structure of MBL is shown in EP0375736B1 May 13, 1998 Aug. 5, 1988.

Nucleic acid, for example, DNA, encoding MBL can be isolated by standard techniques as for instance described in US5270199. For example, oligonucleotide probes specific for the nucleic acid may be constructed and used to probe either genomic or cDNA libraries, as described by Drickamer et al, J. Biol. Chem., 261:6878 (1986), Alternatively, gene fragments from related genes can be used as probes. Preferably, the probe is homologous to a region of the carbohydrate binding domain of MBL. The clones isolated by this technique contain engineered nucleic acid. Once isolated, the gene encoding MBL is useful for producing recombinant MBL, or peptide fragments thereof. In addition, the nucleic acid can be modified by standard techniques in order to express modified peptides. For instance, a human liver cDNA library has been constructed by standard technique as described by Woods et al. Proc. Natl.Acad. Sci. USA. 5661, 1982. This library was probed using a gel purified radiolabelled rat MBL-C cDNA sequence digested with XhoI and EcoRI as described by Drickamer (J. Biol. Chem. 263:9557, 1988). Such probe can be used under non-stringent conditions to identify Potentially useful clones (Kwiatkowski et al. 323 Nature 455, 1986; Messing et al. Proc. Nat. Acad. Sci. USA 74:3642, 1977). A MBL cDNA clone has for instance been used as a probe for human genomic library. Such library can for instance be constructed by standard techniques and clones, which hybridised under stringent conditions can be isolated.

Expression of MBL peptide fragments can be done by standard procedures. For example, the desired region of the MBL encoding DNA, preferably the cDNA, can be

isolated from one of the above-described clones and inserted into any one of several standard expression vectors. A preferred region for expression is that encoding the carbohydrate binding lectin isolated from the coelomic fluid of a sea urchin *A. crassispina* (Giga et al., J. Biol. Chem. 13: 6197, 1987); a chicken cartilage core proteoglycan protein (Shigaku et al., Proc. Natl. Acad. Sci. USA 83:5081, 1986) and the
5 IgE Fc receptor (Ikuta et al., Proc. Natl. Acad. Sci. USA 84:819, 1987).

Antibodies to such expressed peptides or to MBL itself can be produced by standard techniques. They may be monoclonal or polyclonal and are useful for identification
10 of the peptides within animal serum or in clinical diagnostic tests.

A number of carbohydrate-binding proteins (lectins), are known in man. One group is the C-type lectins. The C-type lectins contain a calcium-dependent carbohydrate recognition domain (a C-type CRD) (Weis WI, Taylor ME and Drickamer K (1998)
15 *Immunological Reviews* 163: 19-34). Mannan-binding lectin (MBL), synonymous to mannose-binding lectin, mannan-binding protein or mannose-binding protein (MBP), belongs to the subgroup of C-type lectins, termed collectins. These soluble proteins are composed of subunits presenting three CRDs attached to a collagenous stalk (Holmskov, U., Malhotra, R., Sim, R.B., and Jensenius, J.C. (1994) *Immunol.Today*
20 15:67-74) . MBL interact with carbohydrates presented by a wide range of microorganisms and accumulating evidence shows that it plays an important role in the innate immune defence (Turner, M.W. (1996) *Immunol.Today* 17:532-540).

When bound to carbohydrate MBL is able to activate the complement system. The
25 complement system may be activated via three different pathways: the classical pathway, the alternative pathway, and the mannan-binding lectin (MBL) pathway that is initiated by the binding of MBL to carbohydrates presented by microorganisms. The components of the alternative pathway and of the MBL pathway are parts of the innate immune defence, also termed the natural or the non-clonal, im-
30 mune defence, while the classical pathway involves cooperation with antibodies of the specific immune defence (Janeway CA, et al (1999) *Immunobiology, the immune system in health and disease, Fourth Edition, Churchill Livingstone*).

MBL is synthesised in the liver by hepatocytes and secreted into the blood. It binds to carbohydrate structures on bacteria, yeast, parasitic protozoa and viruses, and exhibits antibacterial activity through killing of the micro-organisms by activation of the terminal, lytic complement components or through promotion of phagocytosis (opsonization). The sertiform structure of MBL is somewhat similar to the bouquet-like structure of C1q, the immunoglobulin-binding subcomponent of the first component in the classical pathway (Turner, M.W. (1996) *Immunol.Today* 17:532-540). C1q is associated with two serine proteases, C1r and C1s, to form the C1 complex. Similarly, MBL is associated with the serine proteases MASP-1 (Matsushita, M. and Fujita, T (1992). *J.Exp.Med.* 176:1497-1502), MASP-2 (Thiel S, et al. *Nature*, 386(6624): 506-510), MASP-3 (Dahl MR, et al. *Immunity*. 2001;15(1):127-35) and an additional protein called MAP19 (Stover CM, et al *J Immunol* 162: 3481-3490). MASP-1, MASP-2 and MASP-3 have modular structures identical to those of C1r and C1s (Dahl MR, et al *Immunity*. 2001;15(1):127-35). The binding of MBL to carbohydrates induces the activation of MASP-1, MASP-2 and MASP-3. Activated MASP-2 then generates the C3 convertase, C4bC2b, through cleavage of the complement factors C4 and C2 (Thiel Set al (1997) *Nature*, 386(6624): 506-510). Reports suggest that MASP-1 may activate C3 directly (Matsushita M. et al *J. Exp. Med.* 1992; 176 (6): 1497-502). The possible substrates for MASP-3 is unknown. Nothing is known about the stoichiometry and activation sequence of the MBL/MASP complexes. MBL has also been characterised in other animals such as rodents, cattle, chicken and monkeys.

The human MBL protein is composed of up to 18 identical 32 kDa polypeptide chains (Lu, J., et al. (1990) *J. Immunol.* 144:2287-2294), each comprising a short N-terminal segment of 21 amino acids including three cysteine residues, followed by 7 repeats of the collagenous motif Gly-X-Y interrupted by a Gln residues followed by another 12 Gly-X-Y repeats. A small 34 residue 'neck-region' joins the C-terminal Ca²⁺-dependent lectin domain of 93 amino acids with the collagenous part of the molecule (Sastry, K., et al. (1989) *J. Exp. Med.* 170:1175-1189).

The collagenous regions of the polypeptide chain combines in subunits composed of these polypeptide chains which are covalently linked by disulphide bridges, both between individual subunits and between the polypeptide chains in each subunit (Turner, M.W. (1996) *Immunol.Today* 17:532-540).

5

The position of these disulphide bridges has, however, not been fully resolved. SDS-PAGE analysis under non-reducing conditions of MBL shows bands with an apparent molecular weight (m.w.) larger than 200 kDa presumably representing blocks of 3×3, 4×3, 5×3 and even 6×3 complexes of covalently assembled subunits (Lu, J., et al. (1990) *J. Immunol.* 144:2287-2294).

10

The actual number of subunits in the natural human MBL protein has been controversial. Lipscombe *et al.* obtained data by use of ultracentrifugation suggesting 25% of human serum MBL to be made of 2-3 trimers and only a minor fraction reaching the size of 6 trimers (Lipscombe, R.J., et al. (1995) *Immunology* 85:660-667). The relative quantification was carried out by densitometry of Western blots developed by chemiluminescence. By SDS-PAGE analysis of fractions from ion exchange chromatography it was found that the predominant species of covalently linked MBL subunit chains consisted of tetramers while only pentameric or hexameric complexes activated complement (Lu, J., et al. (1990) *J. Immunol.* 144:2287-2294.). Gel permeation chromatography (GPC) analysis, in contrast, suggests that MBL is comparable in size with the C1 complex. GPC can be carried out under conditions which allow for a study of the importance of weak protein-protein interactions in the formation of MBL molecules and, in combination with standard MBL assay techniques, also allows for unbiased determination of the MBL content in the GPC fractions.

15

20

25

The concentration of MBL in human serum is largely genetically determined, but reportedly increases up to threefold during acute phase reactions (Thiel S. et al. (1992) *Clin Exp Immunol* 90: 31-35). Three mutations causing structural alterations as well as two mutations in the promotor region are associated with MBL deficiency (Madsen, H.O., et al. (1994) *Immunogenetics* 40:37-44). MBL deficiency is associated with susceptibility to a variety of infections. Examination of five adult individu-

30

als with unusual and severe infections showed three to be homozygous for structural MBL mutations and two to be heterozygous (Summerfield JA, et al (1995) *Lancet* 345: 886-889). Investigation of 229 children referred to the Danish National Hospital because of non-HIV-related immunodeficiency showed a tenfold higher frequency of homozygosity for structural MBL mutant alleles than seen in a control group (Garred P, et al. (1995) *Lancet* 346: 941-943). Allotyping of 617 consecutively hospitalized children at St Mary's Hospital in London showed significantly higher frequency of homozygosity and heterozygosity for mutant allotypes in the infected children than in the noninfected (Summerfield JA, (1997) *BioMed J* 314: 1229-1232).

MBL can bind to a wide range of oligosaccharides. As MBL does not usually recognise self-determinants, but is well suited to interactions with microbial cell surfaces presenting repetitive carbohydrate determinants. *In vitro*, yeast (*Candida albicans* and *Cryptococcus neoformans*), viruses (HIV-1, HIV-2, HSV-2, and various types of influenza A) and a number of bacteria have been shown to be recognised by MBL. In the case of some bacteria, the binding with MBL is impaired by the presence of a capsule (van Emmerik, LC, et al. (1994) *Clin.Exp.Immunol.* 97:411-416). However, even encapsulated bacteria (*Neisseria meningitidis*) can show strong binding of MBL (Jack DL, et al. (1998) *B. J Immunol* 160: 1346-1353).

The micro-organisms, which infect MBL deficient individuals, represent many different species of bacterial, viral and fungal origin (Turner, M.W. (1996) *Immunol.Today* 17:532-540; Summerfield JA, et al. (1997) *BioMed J* 314: 1229-1232). MBL may be a general defence molecule against most bacteria, and thus be a reason why so many bacteria are non-pathogenic.

While accumulating data support the notion of a protective effect of MBL there are also observations suggesting that infections with some micro-organisms, notably intracellular pathogens, attain a higher frequency in MBL sufficient than in MBL deficient individuals (Garred, P, et al. (1994) *Eur.J.Immunogen.* 21:125-131 and Hoal-Van Helden EG, et al (1999) *Pediatr Res* 45:459-64; Hoal-Van Helden EG, et al. (1999) *Pediatr Res* 45:459-64). This is in concordance with the results of an ani-

mal experiment, where an increased number of HSV-2 were found in the liver of mice pre injected with human MBL (Fischer, PB, et al. (1994) Scand J Immunol 39:439-445).

5

We investigated whether a low MBL level affects outcome in non-immunocompromised critically ill patients. Protracted critical illness is associated with substantial metabolic derangement and a high risk of death (Van den Berghe G. et al 2000; 143 (1): 1 – 13). Mortality among patients with prolonged critical illness exceeds 20 percent (Van den Berghe G, et al. N Engl J Med 2001;345(19):1359-67; Takala J, et al. N Engl J Med 1999;341(11):785-92), with most deaths being attributable to sepsis and multiple-organ failure. Each year, these conditions affect more than 500.000 patients in the United States alone (Wheeler AP and Bernard GR. N.Engl.J.Med. 1999;340(3):207-14). An increased susceptibility to severe infections during critical illness, as well as adverse effects of an excessive systemic inflammatory response on organ function may be operative.

Previously MBL infusion has been suggested for treating MBL deficiency in immuno-compromised individuals. Immunocompromised is used in its normal meaning, i.e. an individual not being capable of evoking an immune response towards an infection. MBL deficiency has often been defined by an arbitrary level of about 50 ng/ml. This level is often identical with the sensitivity of various MBL test assays, and the level has therefore been set as the level for which substantially no MBL could be detected. In the case of patients treated with chemotherapy a level of 500 ng/ml has been suggested as defining MBL deficiency in this condition.

By the present invention it has been demonstrated that administrating MBL to ICU admitted patients may reduce the risk of death of subjects that were non-immunocompromised subjects during prolonged ICU stay. The patients in question may have a MBL level below 500 ng/ml serum. Clinical grade MBL is available and has been shown to be safe upon infusion (Garred,-Peter; et al. Pediatr-Pulmonol. 2002 Mar; 33(3): 201-7). Production of recombinant MBL conceivably having a

structure and an activity similar to that of native MBL has been attained (patent application PA 1999 00668/C5/KH).

Summary of the Invention

5

The invention features the use of MBL, purified from natural sources or from material produced by recombinant technologies, or by any other suitable MBL-producing cell line, for the treatment of individuals admitted to ICUs. The MBL may be given before or after start of the treatment and for any duration of time deemed suitable.

10

The invention in one aspect relates to treatment of individuals admitted to ICUs, critically ill patients or to treatment of individuals who are at risk of prolonged ICU admission due to procedures/treatment known to be associated with allocations to ICUs (e.g. major surgery).

15

Accordingly, complications arising during ICU-stay are likely to expose the individual in question to a higher risk of inflammatory conditions and indeed death. It is possible according to the invention to prophylactically treat the patients before or during procedures/treatments (e.g. major surgery) known to be associated with a risk of prolonged ICU admission. By prophylactically treating the ICU- complications before or during a treatment known to be associated with a risk of prolonged ICU admission it is possible to reduce the mortality from sepsis and septic shock arising during the ICU-stay.

20

25

In another aspect the present invention is related to the use of a composition comprising at least one mannan-binding lectin (MBL) polypeptide monomer, or at least one oligomer comprising at least one mannan-binding lectin (MBL) polypeptide monomer, in the manufacture of a medicament for prophylactic, ameliorating or curative treatment of a condition obtained during intensive care, in an individual initially having plasma levels of MBL below 500 ng/ml.

30

In yet another aspect there is provided a method to predict the risk of fatal outcome in an individual allocated to ICUs through measurements of the concentration of MBL in plasma or serum obtained from the individual, and estimation of the probability on the basis of the measured concentration.

5

Definitions

10 The term "systemic inflammatory response syndrome (SIRS)", as used herein refers to the uncontrolled disease process which ensues an initial insult and which gives rise to a multi system disturbance secondary to inflammatory mediators released during shock. It can mean a response to an inflammation or injury that can be infections or non-infectious, defined by having two of the following: 1) Temperature above 38 degrees C or less than 36 degrees C, 2) Heart rate >90, 3) Respiration rate >20 or
15 Paco₂<32 torr, 4) WBC> 12,000/mm³ or <40000, or >10% bands.

The term "Sepsis", as used herein refers to "SIRS", as described above, which is particularly caused by an infectious insult leading to the initial shock phase.

20 The term "Bacteraemia", as used herein means the presence of bacteria in the blood-stream detected by blood cultures.

25 The term "Septic shock" as used herein means Sepsis with a systolic BP <90 mm or drop of 40 mm Hg from baseline value in absence of other causes. Severe sepsis may cause organ dysfunction.

The term "Critical ill patients" (CIP) as used herein means patients which have sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury, a patient who is being operated and where complications supervene, and a patient who has been operated in a vital organ within the last week subject to major surgery within the last week. Usually and preferably, these conditions necessitate prolonged minute to minute therapy an/or observation, usually and preferably in an intensive care unit (ICU) which is a part of an hospital or alike capable of providing a high level of intensive therapy in terms of quality and immediacy. Critical illness might be explained as a disease or state in patients in which death is possible or imminent and whereby the patients are maintained under total or partial parenteral nutrition in an intensive care unit (ICU), a hospital facility or alike for provision of intensive nursing and medical care, characterised by high quality and quantity of continuous monitoring. In a more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has sustained or are at risk of sustaining acutely life-threatening single or multiple organ failure due to disease or injury, or a patient who is being operated and where complications supervene. In a even more restricted sense, the term a "critically ill patient", as used herein refers to a patient who has a sustained or are at risk of sustaining acutely life-threatening single or multiple organ system failure due to disease or injury. Similarly, this definition applies to similar expressions such as 'critical illness in a patient' and a 'patient is critical ill'. Examples of a critically ill patient is a patient in need of cardiac surgery, cerebral surgery, thoracic surgery, abdominal surgery, vascular surgery, or transplantation, or a patient suffering from neurological diseases, cerebral trauma, respiratory insufficiency, abdominal peritonitis, multiple trauma, severe burns, or critical illness polyneuropathy.

Description of the illustrative embodiment

Indication

5 Previously MBL infusion has been suggested for treating MBL deficiency in immuno-compromised individuals. Immunocompromised is used in its normal meaning, i.e. an individual not being capable of evoking an immune response towards an infection. MBL deficiency has often been defined by an arbitrary level of about 50 ng/ml. This level is often identical with the sensitivity of various MBL test assays, and the level
10 has therefore been set as the level for which substantially no MBL could be detected. In the case of patients treated with chemotherapy a level of 500 ng/ml has been suggested as defining MBL deficiency in this condition.

By the present invention administering MBL to ICU admitted patients may reduce
15 the risk of death from sepsis and septic shock during prolonged ICU stay. The patients in question may have a MBL level below 500 ng/ml serum.

Also the treatment of ICU admitted individuals may be conducted by administering MBL to these individuals in combination with relevant antibiotics, anti-viral agents or anti-fungal agents.
20

In particular, individuals at risk of prolonged ICU admission due to a surgical or medical treatment will benefit from prophylactic treatment with MBL before, during and possibly also after the treatment in order to reduce the mortality from complications (sepsis, septic shock or multiple organ deficiency) arising during the ICU-stay.
25

Generally all individuals being allocated to ICUs having a MBL level below 500 ng/ml should be treated with MBL to reduce the risk of death from complications (sepsis and septic shock) arising during the ICU-stay, independent of their specific
30 MBL level. Consequently, in particular individuals having a MBL level below 400 ng/ml will benefit, such as individuals having a MBL level below 300 ng/ml, such as

individuals having a MBL level below 200 ng/ml, such as individuals having a MBL level below 100 ng/ml, such as individuals having a MBL level below 50 ng/ml.

Thus, the present invention in particular relates to the use of MBL polypeptides or blood MBL increasing factors for manufacturing of a medicament for the treatment of individuals having a MBL level in serum in the range of 0-500 ng/ml. The condition may be due to the treatments at ICUs. However, the condition may also be due to a surgical or medical treatment known to be associated with a risk of prolonged ICU admission.

The MBL deficiency may be without known genesis, either acquired or inherited. Individuals, having a MBL level below 500 ng/ml will benefit from MBL treatment in general, in order to prevent ICU induced conditions.

According to one embodiment, the present invention relates to the use of MBL or blood MBL stimulators for the manufacture of a life saving drug to treat or cure a critically ill patient.

According to another embodiment, the present invention relates to a use of MBL or blood MBL stimulators for the manufacture of a medicament to treat or cure a critically ill patient.

According to yet another embodiment, the present invention relates to the use of MBL or blood MBL stimulators for the manufacture of a medicament to prevent that a patient becomes critical ill.

According to a further embodiment, the present invention relates to a use of MBL or blood MBL stimulators for the manufacture of a medicament to increase the survival rate of a critically ill patient.

According to a further embodiment, the present invention relates to a use of MBL or blood MBL stimulators for the manufacture of a medicament to reducing the time a critically ill patient stays within a hospital, for example within an ICU.

- 5 According to a further embodiment, the present invention relates to a use of MBL or blood MBL stimulators for the manufacture of a medicament to prevent treat or cure sepsis and/or its mediators, especially in a critically ill patient.

- 10 According to a further embodiment, the present invention relates to a use of MBL or blood MBL stimulators for the manufacture of a medicament to reduce mortality, hospitality stay, bacteraemia, need for ventilatory support, need for dialysis.

In a further embodiment of present invention, the critically ill patient is a patient in need of cardiac surgery.

15

In a further embodiment of present invention, the critically ill patient is a patient in need of cerebral surgery.

20

In a further embodiment of present invention, the critically ill patient is a patient in need of thoracic surgery.

In a further embodiment of present invention, the critically ill patient is a patient in need of abdominal surgery.

25

In a further embodiment of present invention, the critically ill patient is a patient in need of vascular surgery.

In a further embodiment of present invention, the critically ill patient is a patient in need of transplantation

30

In a further embodiment of present invention, the critically ill patient is a patient suffering from neurological diseases.

In a further embodiment of present invention, the critically ill patient is a patient suffering from cerebral trauma.

5 In a further embodiment of present invention, the critically ill patient is a patient suffering from respiratory insufficiency.

In a further embodiment of present invention, the critically ill patient is a patient suffering from abdominal peritonitis.

10 In a further embodiment of present invention, the critically ill patient is a patient suffering from multiple trauma.

In a further embodiment of present invention, the critically ill patient is a patient suffering from severe burns.

15 In a further embodiment of present invention, the critically ill patient is a patient suffering from critical illness neuropathy.

20 In a further embodiment of present invention, the critically ill patient is a patient being mechanically ventilated.

Furthermore, the present invention relates to a method of selling a substance or a composition of said substance, which stimulate the levels of circulating MBL in a subject by giving information about their novel utility, novel activity and/or novel
25 pharmaceutical indications described herein. One method of selling such blood MBL regulator could be by telling a person, for example a physician, that MBL or a factor which stimulate hepatocytes to synthesise and/or release of MBL and consequently increase the level of circulating MBL maybe used to treat critically ill patients or to reduce the mortality from complications (sepsis and septic shock) arising during the
30 ICU-stay. Alternatively, a method of selling a blood MBL regulators or MBL could be by distributing the above advertising and information, whereby the media are brochures, packaging material which is used for the customer package, any printed ma-

terial/leaflet supplied with the drug, or patient information, labels, web sites, movies, advertising movies, videos, and the like.

Another method of selling a blood MBL regulators or MBL which is covered by the present claims is to support a speaker giving information about the novel utility, indication, and action of the blood glucose regulator according to the present invention or to support an author writing an article giving information about the novel utility, indication, and action of the a blood MBL regulators or MBL according to the present invention. Other variations hereof will be obvious for the skilled art worker, for example distributing and advertisement as the above.

MBL

The MBL composition used to manufacture a MBL medicament may be produced from any MBL source available. The MBL source may be natural MBL, whereby the MBL polypeptides are produced in a native host organism, meaning that MBL is produced by a cell normally expressing MBL. One usual method of producing a MBL composition is by extraction of MBL from human body liquids, such as serum or plasma.

In another aspect the MBL polypeptide oligomers are produced by a host organism not natively expressing a MBL polypeptide, such as by recombinant technology.

In a first embodiment the MBL source may be serum, from which an MBL composition is obtained by purifying serum, plasma, milk product, colostrum or the like by a suitable purification method, such as affinity chromatography using carbohydrate-derivatised matrices, such as mannose or mannan matrices. Such a method is discussed in WO99/64453 which is hereby incorporated by reference.

The MBL composition used to manufacture a MBL medicament preferably comprises MBL oligomers having a size distribution substantially identical to the size distribu-

tion of MBL in serum, such as a size distribution profile at least 80 % identical to the size distribution profile of MBL in serum, more preferred a size distribution profile at least 90 % identical to the size distribution profile of MBL in serum, more preferred a size distribution profile at least 95 % identical to the size distribution profile of MBL in serum.

The matrix may be derivatized with any carbohydrate or carbohydrate mixture where to MBL binds. The matrix is preferably a mannose-, a fucose, a N-acetylglucosamin or a glucose derivatized matrix, such as most preferably a mannose matrix.

The selectivity of the carbohydrate-derivatized matrix is obtained by securing that the matrix as such, i.e the un-derivatized matrix has substantially no affinity to MBL polypeptides. This may be ensured when the matrix as such is carbohydrate-free.

The matrix may be in any form suitable for the chromatography, mostly in the form of beads, such as plastic beads.

After application of the MBL source the column is washed, preferably by using non-denaturing buffers, having a composition, pH and ionic strength resulting in elimination of or lowering of the amount of contaminating proteins, without eluting the MBL. Such as buffer may be TBS (10 mM Tris, 145 mM NaCl, pH 7.4) with calcium ions added. Elution of MBL is performed with a selective desorbing agent, capable of efficient elution of MBL, such as TBS, with added EDTA, and MBL oligomers are collected. Such a purification method is described in International patent application (WO0070043 and WO9937676).

In a preferred aspect a clinical grade MBL composition is obtained by using an MBL source produced by recombinant technology, wherein the MBL source is the culture media from culturing of MBL producing cells.

Thus, the present invention encompasses MBL produced by a process of producing a human recombinant mannan binding lectin (MBL) polypeptide, comprising the steps of:

- 5 - preparing a gene expression construct comprising a DNA sequence encoding a human MBL polypeptide or a functional equivalent thereof,
- transforming a host cell culture with the construct,
- 10 - cultivating the host cell culture, thereby obtaining expression and secretion of the polypeptide into the culture medium, followed by
- obtaining a culture medium comprising human recombinant MBL polypeptides.

15

The culture medium comprising the human recombinant MBL polypeptides may then be purified as described above.

20

The gene expression construct may be produced by conventional methods known to the skilled person, such as described in US patent No. 5,270,199.

25

In another embodiment the gene expression construct is prepared as described in Danish Patent application No: PA 1999 00668 or in International patent application (WO0070043) having the title "Recombinant Human Mannan Binding Lectin").

30

The expression is preferably carried out in e.g. mammalian cells, the preparation according to the invention results from the use of an expression vector comprising intron sequence(s) from an MBL gene and at least one exon sequence. Regarding the transgenic animals as expression system this term is in this context animals which have been genetically modified to contain and express the human MBL gene or fragments or mimics hereof.

In addition to the purification method it is preferred that the gene expression construct and the host cell also favours production of higher oligomers, which has been found to be possible by using a gene expression construct comprising at least one intron sequence from the human MBL gene or a functional equivalent thereof.

5

In particular the MBL composition is used for treatment and/or prophylaxis of sepsis, septic shock or multiple organ failure which occurs in patients treated within the intensive care unit (ICA). Such patients may have post-surgical critical illness, post-traumatic critical illness or patients on ventilator in the ICU.

10

It is an object of present invention to use the MBL composition in a life saving treatment of critically ill patients.

A still further object of present invention is to use the MBL composition to reduce the time a critically ill patients stays within a ICU.

15

Another object of present invention is to use the MBL composition to suppress states of sepsis, septic shock or multiple organ failure.

Another object of present invention is to use the MBL composition to reduce the risk or likelihood from multiple organ failure with a proven septic focus on post-mortem examination in a critically ill patient.

20

Another object of present invention is to use the MBL composition to reduce the mortality, for example, in hospital mortality, in a critically ill patient.

Another object of the present invention is to use the MBL composition to reduce the likelihood of organ replacement therapy and/or organ failure (for instance renal) in a critically ill patient.

25

Another object of present invention is to use the MBL composition to reduce the likelihood of hyperbillirubinemia in a critically ill patient.

Another object of present invention is to use the MBL composition to reduce the likelihood for blood stream infections in a critically ill patient.

Another object of present invention is to use the MBL composition to reduce the likelihood of disturbance in markers of inflammations and/or inflammatory response in a critically ill patient.

30

Another object of present invention is to use the MBL composition to reduce the use of antibiotics in a critically ill patient.

Another object of present invention is to use the MBL composition to reduce the likelihood of a critically ill patient having repetitive positive EMGs.

5 Another object of present invention is to use the MBL composition to reduce the amount of red cell transfusion in a critically ill patient.

Another object of present invention is to use the MBL composition to reduce the need for invasive treatment in a critically ill patient.

10 Compositions

The medicament containing MBL may be produced by using the eluant obtained from the affinity chromatography as such. It is however preferred that the eluant is subjected to further purification steps before being used.

15

In addition to the MBL polypeptide oligomers, the medicament may comprise a pharmaceutically acceptable carrier substance and/or vehicles. In particular, a stabilising agent may be added to stabilise the MBL proteins. The stabilising agent may be a sugar alcohol, saccharides, proteins and/or aminoacids. An example of a stabilising agent may be albumin.

20

Other conventional additives may be added to the medicament depending on administration form for example. In one embodiment the medicament is in a form suitable for injections. Conventional carrier substances, such as isotonic saline, may be used.

25

In another embodiment the medicament is in a form suitable for pulmonal administration, such as in the form of a powder for inhalation or creme or fluid for topical application.

30

The route of administration may be any suitable route, such as intravenously, intramuscularly, subcutaneously or intradermally. Also, pulmonal or topical administration is envisaged by the present invention.

In particular the MBL composition may be administered to prevent and/or treat "ICU complications" in patients having clinical symptoms associated with congenital or acquired MBL deficiency or being at risk of developing such symptoms.

5

The MBL composition may also be administered simultaneously, sequentially or separately with another treatment.

10

The MBL composition is administered in suitable dosages, in particular it is administered at ICU admission and maintained once, twice or thrice a week at least during a part of the stay at ICU, preferably during the whole ICU period.

15

Normally from 1-100 mg is administered per dosage, such as from 2-10 mg, mostly from 5-10 mg per dosage. For other indications the dosage regime may vary.

The use of a MBL composition may also be in a kit-of-parts further comprising an anti-fungal, anti-yeast, anti-bacterial and/or anti-viral medicament. The anti-viral medicament may be a medicament capable of virus attenuation and/or elimination.

20

The invention also relates to an aspect of using a measurement of the MBL level as a prognostic marker for the risk of the individual of acquiring ICU complications and thereby an indicative of the need for treatment. In particular a MBL level below 500 ng/ml is a prognostic marker indicative for treatment with MBL.

25

Thus, the present invention also relates to a method of using a MBL polypeptide composition for preventing and/or reducing "ICU complications" in an individual, the method comprising the steps of:

30

- i) determining serum levels of MBL polypeptide in an individual,
- ii) estimating the probability of the occurrence of ICU complications in the individual, and optionally,

administering a MBL polypeptide composition to the individual.

5 The MBL level is measured in serum or plasma, and may be determined by time resolved immunofluorescent assay (TRIFMA), ELISA, RIA or nephelometry.

Also the MBL levels may be inferred from analysis of genotypes of the MBL genes.

10 The invention has now been explained and accounted for in various aspects, but additionally it will be illustrated below by figure 1 and 2 and table 1 and the non-limiting examples of preferred embodiments.

Figure Legends

15

Figure 1:

Serial measurements of mannan-binding lectin (MBL) concentrations in patients receiving prolonged (> 5 days) intensive care. Bars represents medians, boxes IQRs and whiskers the 10th and 90th percentiles. P value refers to Friedman's test for several related samples

20

Figure 2:

Relative change in MBL concentrations from day 1 ($\Delta\%$) in patients receiving prolonged intensive care.

25

Example

The following example demonstrates the results of an examination of the influence of MBL deficiency on outcome for individuals admitted to intensive care units.

30

Study population

The study encompasses examination of 243 patients on mechanical ventilation admitted to the Department of Intensive Care Medicine, University of Leuven, Leuven, Belgium. All patients included in this study received intensive care for more than 5 days.

Blood stream infection was defined by a blinded investigator as the presence of bacterial pathogens, excluding contamination according to strict criteria (Weinstein MP et al Clin. Infect. Dis. 1997; 24 (4): 584 – 602.), in blood cultures obtained when central body temperature steeply rose above 38.5°C. The use of antibiotics was recorded as the total number of days on any systemic antibiotic treatment. The number of days during which leukopenia (≤ 4000 cells/ μ l) or leukocytosis (≥ 12000 cells/ μ l) was present, and the number of days during which an episode of hypothermia ($\leq 36^\circ\text{C}$) or hyperthermia ($\geq 38^\circ\text{C}$) occurred, were also analysed. The incidence of acute renal failure requiring renal replacement therapy was recorded. Weekly EMG screenings were performed for the diagnosis of critical illness polyneuropathy. The cause of death for all patients who died was established clinically by the attending physician and confirmed on post-mortem examination by a pathologist who was unaware of treatment assignment.

MBL measurements

Blood samples were drawn within 24 h after admission to the ICU (baseline), and subsequently on days 5 and 15 and/or the last day of intensive care (ie. the day of discharge or death) for determination of serum MBL.

Serum MBL concentrations were measured using time-resolved immunofluorometric assay (TRIFMA) (Thiel S et al, Immunology 2002; 204). Microtiter wells (fluoroNunc, Nunc, Denmark) were coated with mannan followed by incubation with diluted test samples and standards.

After washing, europium labelled monoclonal anti-MBL antibody (131-1, Immunolex, Denmark, labelled with europium using reagents from Wallac Oy, Finland) was

added, and after incubation and washing fluorescence enhancement solution was added (Wallac) and the plates were read on a time resolved fluorometre (Delfia 1232, Wallac). The calibration curve was made using dilutions of one plasma, which was kept aliquoted at -80°C . The concentration of MBL in this plasma ($3.6\text{ }\mu\text{g/ml}$) was determined by comparison with highly purified MBL, which was quantified by quantitative amino acid analysis.

An alternative TRIFMA for analysing the MBL is coating Microtitre wells (fluoro-Nunc, Nunc, Karnstrup, Denmark) with antibody by incubation overnight at room temperature with 500 ng anti-human MBL antibody (Mab 131 -1, Statens Serum Institut, Copenhagen, Denmark) in 100 pPBS (0.14 M NaCl, 10 mM phosphate, pH 7.4). After wash with Tween-containing buffer (TBS, 0.14 M NaCl, 10 mM Tris/HCl, 7.5 mM NaN_3 , pH 7.4 with 0.05% Tween20) test samples (plasma 1/20) and calibrator dilutions can be added in TBS/Tween with extra NaCl to 0.5 M and 10 mM EDTA.

After overnight incubation at 40°C and wash, the developing europium-labelled anti-body (12.5 ng Mab 131 -1 labelled with the Eu-containing chelate, isothiocyanato-benzoyl-diethylene-triamine-tetra acetic acid, according to the manufacturer, Wallac, Turku, Finland) can be added in TBS/Tween with 25 pM EDTA.

Following incubation for 2 h and wash, fluorescence enhancement solution is added (Wallac) and the plates are read on a time resolved fluorometre (Delfia 1232, Wallac). The calibration curve is made using dilutions of one plasma, which is kept aliquoted at -80°C .

Collected blood for TRIFMA analysis is drawn into evacuated glass tubes containing EDTA (final concentration about 10 mM). The plasma is aliquoted and kept at -80°C until assay. Plasma samples are similarly obtained from healthy blood donors. The patients are free of infections at the time of blood sampling.

Statistical analysis

Changes in MBL concentrations over time during the ICU-stay were analysed by Friedman's test. Spearman correlation with two-tailed probability values was used to estimate the strength of association between variables. The impact of baseline MBL level on outcome variables (mortality, acute renal failure, bacteremia, prolonged need for antibiotic treatment, polyneuropathy) was assessed by multivariate logistic regression analysis. In addition, multivariate logistic regression analysis was used to assess whether the changes in MBL over time explained clinical outcome variables. Data are given as medians with interquartile ranges unless specified otherwise and statistical significance was assumed for $P < 0.05$. All statistical calculations were performed with Statview 5.0.1. for Macintosh (SAS Institute Inc., North Carolina, USA).

Results

Clinical patient characteristics and outcome

Of the 243 patients included in the study 49 died during intensive care. The cause of death was multiple-organ failure with or without a proven septic focus, acute cardiovascular collapse and severe brain damage.

Bacteraemia occurred in 25% of the patients. The patients received treatment with antibiotics for a median duration of 12 (IQR 6-21) days, leucopenia or leucocytosis was present for a median of 6 (IQR 2-13) days and hypo- or hyperthermia for a median 10 (IQR 5-16) days.

Serum MBL concentrations

Upon ICU admission, the average serum MBL concentration was 820 [IQR 241-1518] $\mu\text{g/l}$ which is comparable with the level documented in healthy Danish and British subjects. The number of patients with a baseline MBL level below 500 ng/ml and below 50 ng/ml was 40% and 8.9%, respectively.

Analysis of the treated patients, non-survivors revealed significantly lower baseline MBL concentrations as compared with survivors (387 [IQR 190-1289] $\mu\text{g/l}$ vs. 897 [IQR 246-1686] $\mu\text{g/l}$, respectively; $P=0.04$, Table 1). The fraction of patients with MBL concentrations below 500 ng/ml was 54 % among non-survivors as compared to 36 % among survivors ($P=0.02$). The fraction of patients with MBL concentrations below 250 ng/ml was 34 % among non-survivors as compared to 25 % among survivors, and the fraction of patients with MBL concentrations below 50 ng/ml was 14 % among non-survivors as compared to 7 % among survivors.

The MBL concentrations increased significantly with time in intensive care ($P<0.0001$, figure 1). This rise was independent of the baseline MBL concentration, and mostly attributable to the survivors. Patients who developed bacteremia revealed a lower relative increase in MBL levels on day 15 compared to those who did not develop bacteremia ($P\leq 0.02$).

Discussion

5 Protracted critical illness is associated with substantial metabolic and immunological derangement and a high risk of death (Van den Berghe G. et al 2000; 143 (1): 1 – 13; Van den Berghe G, et al. N Engl J Med 2001;345(19):1359-67; Takala J, et al. N Engl J Med 1999;341(11):785-92)). We observed that low on-admission concentrations of MBL may predict a poor outcome among patients treated with intensive care.

10

More than two-thirds of patients admitted to intensive care units develop signs of the systemic inflammatory response syndrome (SIRS) (Brun-Buisson C. Intensive Care Med 2000; 26: S64-S74), either caused by infection or tissue damage, and a substantial number of these patients progress to shock and multiple-organ failure.

15

A number of publications have reported a possible association between low levels of MBL and increased risk of infections particularly in patients who are immunocompromised, such as children with immature antibody repertoire (Koch,-A et al. JAMA. 2001 Mar 14; 285(10): 1316-21), patients with AIDS (Kelly,-P. et al Gastroenterology. 2000 Nov; 119(5): 1236-42. Gastroenterology), or patients with malignancies receiving chemotherapy or stem cell transplantation (Neth,-O; et al Lancet. 2001 Aug 25; 358(9282): 614-8; Peterslund,-N-A; Koch,-C; Jensenius,-J-C; Thiel,-S Lancet. 2001 Aug 25; 358(9282): 637-8; Mullighan,-Charles-G; et al. Blood. 2002 May 15; 99(10): 3524-9.).

25

In present invention the current analysis of the 243 ICU treated patients that were not previously immunocompromised revealed that MBL levels on admission were almost three times higher in survivors than in non-survivors, in favour of a vulnerability associated with low MBL levels in critically ill patients who are immunocompetent.

30

The association between low levels of MBL and outcome of treated ICU patients was not restricted to severe MBL deficiency but was evident even when using a concen-

tration of <500 ng/ml as a cut-off level for functional MBL deficiency as previously suggested by Peterslund *et al* (Lancet. 2001 Aug 25; 358(9282): 637-8).

- 5 In conclusion low levels of MBL may predict a poor outcome in protracted critical illness.

		Died in ICU	ICU survivor	P
All patients		n=49	n=194	
MBL concentrations (μ g/l, median [IQR])	Day 1	387 (190-1287)	897 (246-1686)	0.045
	Day 5	460 (158-2140)	1321 (346-2706)	0.012
	Day 15	1855 (181-2594)	1934 (322-3574)	0.376
	Last Day	990 (240-2408)	1960 (569-3848)	0.002

Table 1: Serial measurements of MBL concentrations in patients undergoing prolonged intensive care treatment.

METHODS AND PREPARATIONS FOR CURING CRITICALLY ILL PATIENTS**Claims**

5

1. Use of a regulator of blood mannan-binding lectin (MBL) in the manufacture of a medicament to treat critically ill patients.
2. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to prophylactically treat critically ill patients.
- 10 3. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to ameliorate or cure critically ill patients.
4. Use of a regulator of blood MBL of claim 1, in the manufacture of a life saving drug to prophylactically treat or to cure critically ill patients.
5. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to increase the survival rate in critical ill patients.
- 15 6. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to reduce the time a critically ill patient stays, within the hospital, for example within the intense care unit .
7. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to treat or cure systemic inflammatory response syndrome (SIRS) in critically ill patients.
- 20 8. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to prevent, treat or cure critically ill patient, characterised in that the critically ill patient were previously non-immunocompromised
- 25 9. Use of a regulator of blood MBL of claim 1, in the manufacture of a medicament to reduce mortality, hospital stay, need for dialysis and need for ventilatory support in a critically ill patient.
10. Use of the regulator of blood MBL according to any of the claims 1 to 9, in the manufacture of a medicament to prophylactically or therapeutically
- 30 treat individuals in the ICU having serum levels of MBL below 500 ng/ml.
11. Any of the claims 1 to 10, wherein the blood MBL regulator is a compound of the group of biologically active substances, which stimulate hepatocytes to synthesise and/or release of MBL .

11. Any of the claims 1 to 10, wherein the blood MBL regulator is a compound of the group of biologically active substances, which stimulate hepatocytes to synthesise and/or release of MBL .
12. Any of the claims 1 to 10, wherein the blood MBL regulator is growth hormone or a bioactive derivative thereof.
13. Any of the claims 1 to 10, wherein the blood MBL regulator is a mannan-binding lectin (MBL) polypeptide.
14. Any of the claims 1 to 10, wherein the blood MBL regulator is a composition comprising at least one mannan-binding lectin (MBL) polypeptide monomer, or at least one mannan-binding lectin (MBL) polypeptide oligomer comprising or at least one mannan-binding lectin (MBL) polypeptide monomer.
15. Any of the claims 1 to 10, wherein the composition comprises at least one mannan-binding lectin (MBL) polypeptide oligomer comprising at least one mannan-binding lectin (MBL) polypeptide monomer.
16. Any of the claims 14 to 15, wherein said oligomer is preferably selected from the group of oligomers consisting of trimers, tetramers, pentamers and/or hexamers.
17. Use of any of the claims 1 to 16, wherein the medicament is for the prevention of fatal outcome during intensive care treatment of an individual.
18. Use of any of the claims 1 to 16, wherein the "condition" is multiple organ failure
19. Use of any of the claims 1 to 16, wherein the "condition" is post-surgical critical illness.
20. Use of any of the claims 1 to 16, wherein the "condition" is post-traumatic critical illness.
21. Use of any of the claims 1 to 16, wherein the patient is a patient in need of cardiac surgery, cerebral surgery, thoracic surgery, abdominal surgery, vascular surgery, or transplantation, or a patient suffering from neurological diseases, cerebral trauma, respiratory insufficiency, abdominal peritonitis, multiple trauma, severe burns.

22. Use of any of claims 1-16 in a kit-of-parts further comprising anti-bacterial, anti-viral or anti-fungal medicament.
23. The use of the claims 13 to 16, wherein the MBL polypeptide monomer or the MBL polypeptide oligomer is produced in a native host organism.
- 5 24. The use of claim 23, wherein the native hosts organism is a human cell natively expressing the MBL polypeptide monomer or the MBL polypeptide oligomer.
25. The use of claims 13 to 16, wherein the MBL polypeptide monomer or MBL polypeptide oligomer is produced by a host organism not natively
10 expressing an MBL polypeptide.
26. The use of claims 13 to 16, wherein the MBL polypeptide monomer or the MBL polypeptide oligomer is produced by a method comprising at least one step of recombinant DNA technology in vitro.
27. The use of any of claims 24, 25 and 26, wherein the production of the
15 MBL polypeptide monomer or the MBL polypeptide oligomer is controlled by an expression control sequence not natively associated with MBL polypeptide expression.
28. The use of any of claims 24 to 27, wherein the MBL polypeptide monomer or the MBL polypeptide oligomer is isolated from the host organism.
- 20 29. The use of any of claims 24 to 27, wherein the MBL polypeptide monomer or the MBL polypeptide oligomer is isolated by a method comprising at least one step involving affinity chromatography.
30. The use of claim 29, wherein the affinity chromatography step is capable of isolating MBL polypeptide trimers, tetramers, pentamers and/or hex-
25 amers from a composition further comprising additional MBL polypeptide oligomers and/or MBL polypeptide monomers.
31. The use of any of claims 24 to 30, wherein the MBL polypeptide monomer and/or the MBL polypeptide oligomer is free from any impurities naturally associated with the MBL polypeptide when produced in a native host or-
30 ganism.
32. The use of any of the claims 13 to 21, wherein the MBL polypeptide monomer is a mammalian MBL polypeptide monomer.

33. The use of claim 32, wherein the mammalian MBL polypeptide monomer is a human MBL polypeptide monomer.
34. The use of any of the claims 13 to 21, wherein the MBL polypeptide oligomer comprises MBL polypeptide monomers according to any of claims
5 30 to 32.
35. The use of claims 1 to 34, wherein the medicament is administered to the individual prior to another treatment at ICUs.
36. The use of claims 1 to 34, wherein the medicament is administered to the individual simultaneously, sequentially or separately with another treat-
10 ment.
37. The use of claim 1 to 34, wherein the medicament is administered to the individual prior to, during and after said other treatment.
38. The use of any of the preceding claims, wherein the treatment is a prophylactic treatment.
- 15 39. The use of any of claims 13 to 38, wherein the medicament is a booster of MBL polypeptide serum levels in an individual having MBL polypeptide serum levels below a predetermined minimum MBL polypeptide serum level.
40. The use of any of the claims 1 to 39, wherein the individual has serum
20 levels of MBL polypeptide is below 500 ng/ml.
41. The use of any of the claims 1 to 39, wherein the individual has serum levels of MBL polypeptide below 400 ng/ml.
42. The use of any of the claims 1 to 39, wherein the individual has serum levels of MBL polypeptide below 300 ng/ml.
- 25 43. The use of any of the claims 1 to 39, wherein the individual has serum levels of MBL polypeptide below 200 ng/ml.
44. The use of any of the claims 1 to 39, wherein the individual has serum levels of MBL polypeptide below 100 ng/ml.
45. The use of any of the claims 1 to 39, wherein the individual has serum
30 levels of MBL polypeptide below 50 ng/ml.

46. The use of any of the preceding claims, wherein serum or plasma levels of MBL polypeptide in the individual are determined by quantitative analysis.
- 5 47. The use of the claims 41 to 48, wherein the analysis comprises at least one of ELISA, TRIFMA, RIA or nephelometry.
48. Method of using a MBL polypeptide composition for preventing and/or reducing inflammation and/or death in an individual, the method comprising the steps of:
- 10 i) determining serum levels of MBL polypeptide in an individual,
- ii) estimating the probability of the occurrence of intensive care complications in the individual, and optionally,
- 15 iii) administering a MBL polypeptide composition to an individual.
49. Advertising media and material and information media and material having or giving information about the indications and utilities of a regulator of blood MBL levels, preferably MBL itself or any of said regulators or their compositions described in any of the claims 1 to 48.
- 20 50. A method of selling a regulator of blood MBL levels, preferably MBL itself or any of said regulators or their compositions described in any of the claims 1 to 50 by giving information of about the indications and utilities.

Figure 1.





Figure 2



INTERNATIONAL SEARCH REPORT

International Application No

PCT/B/03/00158

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 A61P00/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, EMBASE, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>GARRED PETER ET AL: "Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome." THE JOURNAL OF INFECTIOUS DISEASES. UNITED STATES 1 NOV 2003, vol. 188, no. 9, 1 November 2003 (2003-11-01), pages 1394-1403, XP009024751 ISSN: 0022-1899 the whole document</p> <p style="text-align: center;">--- -/--</p>	1-48



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

28 January 2004

Date of mailing of the international search report

18/02/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fayos, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/BE 03/00158

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 24919 A (LEUVEN K U RES & DEV ;DEN BERGHE GRETA HERMAN VAN (BE); ZEGHER FRA) 21 September 1995 (1995-09-21) claims 1,5 page 3, line 33 - line 36 examples 1-7 ----	1-9,11, 12, 17-21, 35-38
X	WO 99 64453 A (STATENS SERUMINSTITUT ;LAURSEN INGA (DK)) 16 December 1999 (1999-12-16) claims 24-26 page 17, line 16 - line 34 ----	1-48
X	WO 02 05833 A (FISCHER PER ;NATLMMUNE APS (DK)) 24 January 2002 (2002-01-24) the whole document ----	1-48
X	KILPATRICK DAVID C: "Mannan-binding lectin: clinical significance and applications." BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 19 SEP 2002, vol. 1572, no. 2-3, 19 September 2002 (2002-09-19), pages 401-413, XP004380529 ISSN: 0006-3002 the whole document in particular 5. p 408-409 ----	1-48
Y	WO 00 24398 A (BRISTOL MYERS SQUIBB CO) 4 May 2000 (2000-05-04) claims 14,15 ----	1-9,11, 12, 17-21, 35-38
Y	HIBBERD M L ET AL: "Variation in the mannose binding lectin (MBL) gene and susceptibility to sepsis" SEPSIS 2001 NETHERLANDS, vol. 4, no. 3, 2001, pages 201-207, XP009024789 ISSN: 1385-0229 page 203, column 2, paragraph 3 -page 204, column 2, paragraph 6 abstract ----- -/--	1-48

INTERNATIONAL SEARCH REPORT

International Application No
PCT/BE 03/00158

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HANSEN TROELS KRARUP ET AL: "GH strongly affects serum concentrations of mannan-binding lectin: Evidence for a new IGF-I independent immunomodulatory effect of GH" JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 86, no. 11, November 2001 (2001-11), pages 5383-5388, XP002268239 ISSN: 0021-972X the whole document	1-9,11, 12, 17-21, 35-38
Y	GARRED P ET AL: "Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis." THE JOURNAL OF CLINICAL INVESTIGATION. UNITED STATES AUG 1999, vol. 104, no. 4, August 1999 (1999-08), pages 431-437, XP002268240 ISSN: 0021-9738 abstract discussion	1-48
P,X	HANSEN TROELS KRARUP ET AL: "Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels." THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM. UNITED STATES MAR 2003, vol. 88, no. 3, March 2003 (2003-03), pages 1082-1088, XP009024778 ISSN: 0021-972X the whole document	1-48
P,X	GARRED PETER ET AL: "Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome in patients with systemic inflammatory response syndrome." MOLECULAR IMMUNOLOGY, vol. 40, no. 2-4, September 2003 (2003-09), page 206 XP009024781 9th European Complement Workshop;Trieste, Italy; September 06-09, 2003 ISSN: 0161-5890 (ISSN print) abstract	1-48
P,Y	WO 03 010188 A (MATTHIESEN FINN ;NATIMMUNE AS (DK)) 6 February 2003 (2003-02-06) claims 37-49 page 25, line 20 -page 26, line 3	1-48

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/BE 03/00158

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	<p>EP 1 344 533 A (NATIMMUNE AS) 17 September 2003 (2003-09-17) page 14, paragraph 141 -page 1, paragraph 150 claims 45-51</p>	1-48

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-11, 17-22, 35-47 (all partially)

Present claims 1-11, 17-22 and 35-47 relate to a product/compound defined by reference to a desirable characteristic or property, namely its ability to regulate blood MBL ("regulator of blood MBL").

The claims cover all products/compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products/compounds being GH (claim 12) or as specified in claims 13-16.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/BE 03/00158

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 49-50
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(v) PCT - Presentation of information; Rule 39.1(iii) PCT - Scheme, rules and method for doing business
2. ☒ Claims Nos.: 1-11, 17-22, 35-47 (all partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/BE/00158

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9524919	A	21-09-1995	AU 1942995 A WO 9524919 A1 NL 9401045 A	03-10-1995 21-09-1995 02-10-1995
WO 9964453	A	16-12-1999	AU 764066 B2 AU 4134399 A CA 2334696 A1 WO 9964453 A1 EP 1084143 A1 JP 2002517513 T NZ 509089 A US 6429192 B1	07-08-2003 30-12-1999 16-12-1999 16-12-1999 21-03-2001 18-06-2002 25-10-2002 06-08-2002
WO 0205833	A	24-01-2002	AU 7841601 A WO 0205833 A1 EP 1303288 A1	30-01-2002 24-01-2002 23-04-2003
WO 0024398	A	04-05-2000	AU 749970 B2 AU 1598300 A CA 2348023 A1 EP 1126854 A1 JP 2002528417 T WO 0024398 A1 US 6380184 B1	04-07-2002 15-05-2000 04-05-2000 29-08-2001 03-09-2002 04-05-2000 30-04-2002
WO 03010188	A	06-02-2003	WO 03010188 A1	06-02-2003
EP 1344533	A	17-09-2003	WO 03077937 A1 EP 1344533 A1 US 2004006009 A1	25-09-2003 17-09-2003 08-01-2004

Box No. VIII (iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America)
The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the specific Notes to Box No. VIII (iv). If this Box is not used, this sheet should not be included in the request.

**Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv))
 for the purposes of the designation of the United States of America:**

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This declaration is directed to international application No. PCT/ BE 03/00158 (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

Prior Applications: 23 September 2002 .- 0222014.3: GB

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by 37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the PCT international filing date of the continuation-in-part application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

VAN DEN BERGHE Greta


Name: rue de Beaumont 77

Residence: 1390 Grez-Doiceau

(city and either US state, if applicable, or country) Belgium

Mailing Address:

Citizenship: BE

Inventor's Signature:  Date: 06/10/03
 (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent) (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)


Name: **THIEL Steffen** Nordtøftevej 11

Residence: 8240 Risskov

(city and either US state, if applicable, or country) Denmark

Mailing Address:

Citizenship: DK

Inventor's Signature:  Date: 19/10/03
 (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent) (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)

☒ This declaration is continued on the following sheet, "Continuation of Box No. VIII (iv)".

Continuation of Box No. VIII (i) to (v) DECLARATION

If the space is insufficient in any of Boxes Nos. VIII (i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII ..." (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.

INVENTORS

KRARUP HANSEN Troels
Bygvangen 20
8200 Aarhus N
Denmark

Signatures



Date

22/10/03